Leading the Way in Life Science Technologies

GEN Exclusives

More »

GEN News Highlights

More »
March 7, 2011

AstraZeneca Teams Up with Galderma to Develop Dermatological Therapies

  • AstraZeneca and Galderma Pharma are joining forces to develop treatments for dermatological conditions. Galderma will evaluate compounds from AstraZeneca’s existing pipeline for their potential to treat a range of skin diseases like acne, atopic dermatitis, and psoriasis.

    According to the deal Galderma will have exclusive access to a number of AstraZeneca’s compounds. Initial targets have already been identified from disease areas as diverse as oncology, inflammation, and central nervous system disorders.

    “This partnership is an example of how we are leveraging our science in new and creative ways through collaborations with recognized experts outside of AstraZeneca’s core therapy areas,” notes Clive Morris, head of the new opportunities innovative medicines unit at AstraZeneca. “Partnering with Galderma, a world leader in dermatology, is the most efficient and effective way to unlock the potential of our compounds in this rapidly evolving disease area.”

    Galderma was founded in 1981 and has 31 affiliates around the world. The firm says that it invests approximately 20% of its sales each year to discover and develop new products and access innovative technologies. The company’s laboratory in Sophia-Antipolis is focused exclusively on dermatology.

Related content

  • Finally! A cure for the Biotech News Blues.

  • Join 110,000 colleagues who rely on GEN Highlights for breaking news and exclusive articles shaping today’s life science tools and technologies.

  • Oops! Please type your email in the following format: yourname@example.com An error has occurred. Please contact Customer Service at contactGEN@genengnews.com
  • You’re all set! Thank you for subscribing to GEN Highlights.